Exogen Inc. announces initial public offering

Business Wire, July 20, 1995

PISCATAWAY, N.J.--(BUSINESS WIRE)--July 20, 1995--Exogen Inc. ("Exogen Inc." or the "company"; NASDAQ, NMS: EXGN) announced on July 19, 1995 an initial public offering of 2,500,000 shares of its common stock at a price of $11 per share.

All of the shares are being sold by Exogen Inc. The offering is being managed by Robertson, Stephens & Company, L.P., Cowen & Company and Piper Jaffray Inc.

Exogen designs, develops, manufactures and markets medical devices for the non-invasive treatment of musculoskeletal injury and disease. The company's proprietary ultrasound and mechanical stress technologies are based on the principle that bone growth is stimulated by mechanical force. The company's Sonic Accelerated Fracture Healing System (SAFHS) device utilizes its proprietary ultrasound technology to accelerate fracture healing for certain closed, cast-immobilized, fresh fractures of the lower leg and lower forearm. The company's pre-market approval application for the SAFHS 2A device was approved by the U.S. Food and Drug Administration in October 1994. The company's SAFHS device is the only medical device approved by the FDA for the acceleration of new fracture healing.

Copies of the final prospectus relating to the offering may be obtained from Robertson, Stephens & Company, L.P., 555 California St., Suite 2600, San Francisco, CA 94104, 415/781-9700; Cowen & Company, Financial Square, New York, NY 10005, 212/495-6000; or Piper Jaffray Inc., Piper Jaffray Tower, 222 S. Ninth St., Minneapolis, MN 55402, 612/342-6000.

CONTACT: Exogen Inc., Piscataway

Patrick A. McBrayer, 908/981-0990